About amphastar pharmaceuticals inc - AMPH
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
AMPH At a Glance
Amphastar Pharmaceuticals, Inc.
11570 6th Street
Rancho Cucamonga, California 91730
| Phone | 1-909-980-9484 | Revenue | 719.89M | |
| Industry | Pharmaceuticals: Major | Net Income | 98.09M | |
| Sector | Health Technology | Employees | 1,976 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AMPH Valuation
| P/E Current | 10.052 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.163 |
| Price to Sales Ratio | 1.794 |
| Price to Book Ratio | 1.55 |
| Price to Cash Flow Ratio | 8.27 |
| Enterprise Value to EBITDA | 8.163 |
| Enterprise Value to Sales | 2.309 |
| Total Debt to Enterprise Value | 0.395 |
AMPH Efficiency
| Revenue/Employee | 364,315.283 |
| Income Per Employee | 49,642.713 |
| Receivables Turnover | 5.015 |
| Total Asset Turnover | 0.436 |
AMPH Liquidity
| Current Ratio | 4.021 |
| Quick Ratio | 2.903 |
| Cash Ratio | 1.804 |
AMPH Profitability
| Gross Margin | 47.432 |
| Operating Margin | 19.503 |
| Pretax Margin | 17.173 |
| Net Margin | 13.626 |
| Return on Assets | 5.942 |
| Return on Equity | 12.898 |
| Return on Total Capital | 6.789 |
| Return on Invested Capital | 6.979 |
AMPH Capital Structure
| Total Debt to Total Equity | 83.164 |
| Total Debt to Total Capital | 45.404 |
| Total Debt to Total Assets | 39.101 |
| Long-Term Debt to Equity | 81.951 |
| Long-Term Debt to Total Capital | 44.742 |